NCT06894329 A Study for the PanCystPro Assay in the Management of Pancreatic Cystic Lesions
| NCT ID | NCT06894329 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amplified Sciences Inc |
| Condition | Pancreatic Cystic Lesions |
| Study Type | OBSERVATIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-02-17 |
| Primary Completion | 2026-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 50 participants in total. It began in 2026-02-17 with a primary completion date of 2026-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this research is to learn if the PanCystPro assay can help doctors in making decisions about treatment and monitoring of pancreatic cysts. The PanCystPro test measures glucose, carcinoembryonic antigen (CEA), and gastricsin biomarkers on fluid obtained from a pancreatic cyst. The test reports if the cyst fluid should be considered "Non-mucinous" or "Mucinous". Mucinous pancreatic cysts are more likely to progress to cancer while non-mucinous cysts seldom progress to cancer.
Eligibility Criteria
Inclusion Criteria: * Patients 18 years of age or older * Cross sectional imaging studies demonstrating a pancreatic cyst at least 12 mm in size where fluid sampling can aid in patient's management * Written informed consent. * The patient will be undergoing EUS with anticipated FNA extraction as part of standard patient care. Exclusion Criteria: * Patients diagnosed with pancreatic cancer. * Pregnant or lactating females. * Patients with contraindications to moderate or deep procedural sedation (necessary for the conduct of the endoscopic ultrasound) like major cardiorespiratory illness. * Patients with contraindications to FNA of a pancreatic cyst like being on blood thinners.
Frequently Asked Questions
Who can join the NCT06894329 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreatic Cystic Lesions. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06894329 currently recruiting?
Yes, NCT06894329 is actively recruiting participants. Visit ClinicalTrials.gov or contact Amplified Sciences Inc to inquire about joining.
Where is the NCT06894329 trial being conducted?
This trial is being conducted at Indianapolis, United States, Boston, United States, New Brunswick, United States.
Who is sponsoring the NCT06894329 clinical trial?
NCT06894329 is sponsored by Amplified Sciences Inc. The trial plans to enroll 50 participants.